Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback